Tandem Integrates Libre 3 Plus with Insulin Pump in Europe

Tandem Diabetes Care (TNDM) announced in July 2026 that its t:slim X2 insulin pump with Control-IQ+ technology is now compatible with Abbott's FreeStyle Libre 3 Plus CGM in the UK, Switzerland, Sweden, Finland, and Italy. This integration provides pump users with an additional CGM choice, featuring 15-day sensors that deliver minute-by-minute glucose data.

The Product

The integration pairs Tandem's advanced AutoBolus-enabled AID algorithm with one of Europe's most widely used CGM platforms. The system allows patients to use the Libre 3 Plus sensor for up to 15 days without frequent replacements, continuously streaming glucose data to the pump for automated insulin adjustments.

Pricing and Availability

Pricing details have not been disclosed, but the system is expected to be available immediately in the mentioned markets through standard distribution channels.

Competition

This integration strengthens Tandem's competitive position against Medtronic and Insulet by offering an open-choice CGM option. It also expands the reach of Libre 3 Plus, which competes with Dexcom G7.

Potential Impact on the Company

The integration is expected to boost Tandem's user base in Europe, particularly among patients who prefer the Libre system. It reinforces Tandem's leadership in open-protocol insulin delivery systems, potentially driving future revenue growth.